2. Cell Cycle/DNA Damage Epigenetics Autophagy
  3. PARP Autophagy Mitophagy
  4. Olaparib

Olaparib  (Synonyms: AZD2281; KU0059436)

Cat. No.: HY-10162 Purity: 99.98%
COA
SDS
Handling Instructions Technical Support

Olaparib (AZD2281; KU0059436) est un inhibiteur puissant de PARP et actif par voie orale avec des IC50s de 5 et 1 nM pour PARP1 et PARP2, respectivement. Olaparib est un activateur de l'autophagie et de la mitophagie.

Olaparib (AZD2281; KU0059436) ist ein potenter und oral aktiver PARP-Inhibitor mit IC50s von 5 bzw. 1 nM für PARP1 und PARP2. Olaparib ist ein autophagy und mitophagy -Aktivator..

Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB).

For research use only. We do not sell to patients.

CAS No. : 763113-22-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g In-stock
2 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 347 publication(s) in Google Scholar

Other Forms of Olaparib:

Olaparib Related Antibodies

Top Publications Citing Use of Products

347 Publications Citing Use of MCE Olaparib

Flow Cytometry
Bio/Physico-chemical Assay
WB
RT-PCR
Cell Proliferation/Viability Assay
2D/3D Cell Culture and Differentiation
IHC
Gel Electrophoresis
IF

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495.  [Abstract]

    Cell viability in control or BRCA1-reconstituted UWB1.289 cells treated with PARPi (olaparib or niraparib, 42 hours) and/or RSL3 (18 hours).

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2024 Aug 2;14(8):1476-1495.  [Abstract]

    Cell viability in BRCA1-sgRNA–infected or control HS578T cells treated with olaparib (42 hours) and/or RSL3 (18 hours).

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151.  [Abstract]

    Olaparib (1-3 μM) significantly inhibits the viability of sensitive cells (A2780) but exhibits reduced efficacy against resistant cells (A2780-OlaR), with IC50 values of 5.362 μM and 168.251 μM, respectively, for A2780 and A2780-OlaR cells.

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151.  [Abstract]

    Olaparib (10 μM) significantly induces DNA damage in sensitive cells (A2780).

    Olaparib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Sep 12:77:101151.  [Abstract]

    Olaparib (10 μM; 2-4 h) significantly induces DNA damage in sensitive cells (A2780).

    Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183.  [Abstract]

    Cells were treated with indicated concentrations of olaparib (50-200 μM) for 6 h, and the levels of 47 S pre-rRNA were determined by qRT-PCR to assess the extent of ribosomal stress.

    Olaparib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183.  [Abstract]

    Cell viability assay was performed for Olaparib treated ovarian cancer organoids with/without pretreatment with the listed drugs.

    Olaparib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2023 Dec 11;51(22):12242-12260.  [Abstract]

    Dot blot analysis of telomere DNA contents in the indicated ChIP and input from U2OS cells treated with either 1 μM Olaparib (OLP) or 2 μM STL127705 (STL) for 24 h.

    Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507.  [Abstract]

    MitoParaquat (0.1 μM, 30 min) abolished the inhibition of platelet aggregation by nicotinamide riboside (1 mM, 30 min) or olaparib (20 μM, 30 min) in resting platelets from LST patients.

    Olaparib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102507.  [Abstract]

    MitoParaquat (0.1 μM, 30 min) did not interrupt the improvements in mitochondrial respiration induced by nicotinamide riboside (1 mM) or olaparib (20 μM) in resting platelets from LST patients.

    Olaparib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Oct 11;41(2):111462.  [Abstract]

    With an alternative ROS scavenger, the vitamin E analog Trolox, Olaparib-induced ROS production was similarly suppressed

    Olaparib purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2019 Feb 4;26(1):14.   [Abstract]

    Inhibition of NFBD1 results in defective γ-H2AX foci formation after Olaparib exposure, cells are exposed to Olaparib for 24 h, and the γ-H2AX positive cells are determined by FCM

    Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 May:43:225-237.  [Abstract]

    Representative images of immunohistochemical staining for proteins as indicated in A2780 xenografted tumors (n=6 per treatment group) treated with Olaparib and PD 0332991 either as single-agents or in combination for 4 days.

    Olaparib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2019 Jun:44:419-430.  [Abstract]

    Immunoblots (IB) are done to detect γH2AX and DNA repair proteins, Ku80 and RAD51 using UAB-PA4 or UAB-PA16 tumors harvested from mice 24 h following final treatment. Quantitation by densitometry of results is shown below each IB image.

    Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53.  [Abstract]

    Combination of RAD001 with Olaparib (left panel) and AZD2014 with Olaparib (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165.  [Abstract]

    The expression of CCND1mRNA and cyclin D1 protein level in A2780 and SKOV3 cells is analyzed by western blot after Olaparib treatment at IC50 concentrations.

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165.  [Abstract]

    Immunohistochemistry for CCND1 is performed in tumor samples in the treatment of compounds (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated).

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165.  [Abstract]

    CCDN1 protein level in tumor samples of different treatment groups (control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated) are analyzed by western blot.

    Olaparib purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2019 Jan;152(1):157-165.  [Abstract]

    Immunohistochemistry of RAD51 and γ-H2AX in samples of SKOV3 tumors. Representative sections are taken from tumor tissue of control, scrambled shRNA treated, Olaparib + scrambled shRNA treated, or Olaparib + CCND1-shRNA treated mice.

    Olaparib purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Jan 18;37(3):341-351.  [Abstract]

    PTEN-deficient endometrioid endometrial cancer cell lines are treated with drugs as indicated for 24 h. Phosphorylated AKT, S6RP and 4EBP1 proteins and cleaved PARP are detected by western blot. Vinculin served as a loading control.

    Olaparib purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Dec;17(12):2676-2688.  [Abstract]

    EW8 and TC71 cells are treated with Olaparib (5 μM) or U0126 (5 μM) for 24 hours and then protein synthesis is assessed using puromycin labeling.

    Olaparib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Apr;39(4):1747-1756.  [Abstract]

    The effect of Olaparib on protein expression. Western blot assays of MUS81 and MCM2 expression levels in A2780 and SKOV3 cells after treatment with 5 μM Olaparib compared with a blank control.

    Olaparib purchased from MedChemExpress. Usage Cited in: Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867.  [Abstract]

    PARP1 inhibition is lethal to MPM cells. Colony formation assays of clonal cell survival with continuous Niraparib or Olaparib, both at 3 uM. a H2452 BPA1-mutant MPM cells exposed to Niraparib. b HMeso01A BAP1-mutant MPM cells exposed to Niraparib. cHMeso01A BAP1-mutant MPM cells exposed to Olaparib. d CRL-2081 BAP1 wild-type MPM cells exposed to Olaparib. e CRL-2081 BAP1 wild-type MPM cells exposed to Niraparib. f Dose response of H2452 BPA1-mutant MPM cells exposed to varying concentrations of

    Olaparib purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2016 Feb 24;17(3):272.  [Abstract]

    The effect of AZD2281 on the protein expression of xenografted HSC-2 tumors. Relative band intensity of western blot data is normalized by the expression level of β-actin; The proteins analyzed are PARP-1 (poly(ADP-ribose) polymerase-1).

    View All PARP Isoform Specific Products:

    View All Isoforms
    PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB)[1][2][3][4][5][6].

    IC50 & Target[1]

    PARP-2

    1 nM (IC50)

    PARP-1

    5 nM (IC50)

    tankyrase-1

    1.5 μM (IC50)

    Autophagy

     

    Mitophagy

     

    Cellular Effect
    Cell Line Type Value Description References
    A-375 IC50
    12.71 μM
    Compound: AZD2281
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    A2780 IC50
    1 μM
    Compound: Olaparib, KU-59436, AZD 2281
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    		[PMID: 24398383]
    A549 IC50
    28 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    A549 IC50
    29.5 μM
    Compound: Olaparib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 37832229]
    A549 IC50
    31.6 μM
    Compound: AZD2281
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    A549 IC50
    5.89 μM
    Compound: Olaparib
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability
    		[PMID: 35643262]
    A549 IC50
    6.06 μM
    Compound: Olaparib
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    		[PMID: 37832229]
    A549 IC50
    > 200 μM
    Compound: A1
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    AML12 CC50
    31.09 μM
    Compound: Olaparib
    Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay
    Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 7 days by MTT assay
    		[PMID: 35504210]
    BT-549 IC50
    35.25 μM
    Compound: Ola
    Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay
    		[PMID: 38134746]
    BT-549 IC50
    6610 nM
    Compound: Olaparib
    Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38039793]
    Bel-7402 IC50
    35.5 μM
    Compound: Olaparib
    Antiproliferative activity against human Bel-7402 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 30844273]
    C-33-A IC50
    > 200 μM
    Compound: A1
    Antiproliferative activity against human C-33-A cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human C-33-A cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    CAPAN-1 EC50
    259 nM
    Compound: 2; AZD-2281
    Cytotoxicity against BRCA2-deficient human Capan1 cells
    Cytotoxicity against BRCA2-deficient human Capan1 cells
    		[PMID: 26652717]
    CAPAN-1 IC50
    0.027 μM
    Compound: 5; OLA
    Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 13 days by by CCK-8 assay
    Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 13 days by by CCK-8 assay
    		[PMID: 32924477]
    CAPAN-1 IC50
    0.053 μM
    Compound: OL
    Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35780655]
    CAPAN-1 IC50
    0.053 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    Antiproliferative activity against human BRCA2 -/- CAPAN-1 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    		[PMID: 35430559]
    CAPAN-1 IC50
    0.53 μM
    Compound: 1; AZD2281
    Antiproliferative activity against BRCA2-deficient human CAPAN-1 cells assessed as inhibition of cell proliferation incubated for 7 days by CellTiter-Glo assay
    Antiproliferative activity against BRCA2-deficient human CAPAN-1 cells assessed as inhibition of cell proliferation incubated for 7 days by CellTiter-Glo assay
    		[PMID: 35785724]
    CAPAN-1 IC50
    1.67 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability
    Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability
    		[PMID: 35643262]
    CAPAN-1 IC50
    2.61 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    CAPAN-1 IC50
    25.2 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay
    		[PMID: 35091172]
    CAPAN-1 IC50
    399.3 nM
    Compound: 1; AZD-2281
    Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay
    Antiproliferative activity against human Capan1 cells after 7 days by CCK8 or SRB assay
    		[PMID: 28692916]
    CAPAN-1 IC50
    5.34 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    		[PMID: 35091172]
    CAPAN-1 IC50
    6.3 μM
    Compound: Olaparib, KU-59436, AZD 2281
    Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay
    Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay
    		[PMID: 24398383]
    CAPAN-1 IC50
    60.66 μM
    Compound: A1
    Antiproliferative activity against human CAPAN-1 cells harboring BRCA1 mutant assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human CAPAN-1 cells harboring BRCA1 mutant assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    CAPAN-1 IC50
    7582.42 nM
    Compound: OP
    Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against human Talazoparib-resistant CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    CAPAN-1 IC50
    764 nM
    Compound: OP
    Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against human CAPAN-1 cells assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    CAPAN-1 IC50
    8.42 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability after 4 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 34813314]
    CAPAN-1 IC50
    8.42 μM
    Compound: Olaparib
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    		[PMID: 35091172]
    CAPAN-1 IC50
    83.1 μM
    Compound: Ola
    Antiproliferative activity against BRCA2-deficient human Capan1 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA2-deficient human Capan1 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    CFPAC-1 IC50
    13.7 μM
    Compound: Olaparib
    Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability after 4 days by MTT assay
    Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 34813314]
    CFPAC-1 IC50
    13.7 μM
    Compound: Olaparib
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    		[PMID: 35091172]
    CFPAC-1 IC50
    28.7 μM
    Compound: Olaparib
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 3 days by MTT assay
    		[PMID: 35091172]
    CFPAC-1 IC50
    7.44 μM
    Compound: Olaparib
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    CFPAC-1 IC50
    9.87 μM
    Compound: Olaparib
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    		[PMID: 35091172]
    CWR22R IC50
    33.8 μM
    Compound: Olaparib
    Growth inhibition of human 22Rv1 cells after 5 days by SRB assay
    Growth inhibition of human 22Rv1 cells after 5 days by SRB assay
    		[PMID: 32484346]
    Caco-2 IC50
    65.5 μM
    Compound: Olaparib
    Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 30844273]
    DLD-1 EC50
    0.1 μM
    Compound: 2
    Antiproliferative activity against BRCA deficient human DLD1 cells by Celltiter-Glo assay
    Antiproliferative activity against BRCA deficient human DLD1 cells by Celltiter-Glo assay
    		[PMID: 31303996]
    DLD-1 EC50
    19 μM
    Compound: 2
    Antiproliferative activity against human DLD1 cells by Celltiter-Glo assay
    Antiproliferative activity against human DLD1 cells by Celltiter-Glo assay
    		[PMID: 31303996]
    DLD-1 IC50
    0.042 μM
    Compound: 1
    Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days
    Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days
    		[PMID: 34570508]
    DLD-1 IC50
    0.401 μM
    Compound: 1
    Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
    Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
    		[PMID: 37484567]
    DLD-1 IC50
    1.91 μM
    Compound: 1
    Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    DLD-1 IC50
    13.72 μM
    Compound: Olaparib
    Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36921527]
    DLD-1 IC50
    14.7 μM
    Compound: 1
    Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
    Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
    		[PMID: 37484567]
    DLD-1 IC50
    171.8 nM
    Compound: Olaparib
    Antiproliferative activity against human DLD-1 cells harbouring BRCA-2 mutant assessed as inhibition of cell growth
    Antiproliferative activity against human DLD-1 cells harbouring BRCA-2 mutant assessed as inhibition of cell growth
    		[PMID: 36343904]
    DLD-1 IC50
    2.29 μM
    Compound: 1
    Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human DLD1 cells expressing BRCA2 knockout assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    DLD-1 IC50
    23.326 μM
    Compound: Olaparib
    Antiproliferative activity against human DLD-1 cells harbouring wild type BRCA assessed as inhibition of cell growth
    Antiproliferative activity against human DLD-1 cells harbouring wild type BRCA assessed as inhibition of cell growth
    		[PMID: 36343904]
    DLD-1 IC50
    25.7 μM
    Compound: 1
    Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    DLD-1 IC50
    26.8 μM
    Compound: 1
    Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human DLD1 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    DU-145 IC50
    11.44 μM
    Compound: Olaparib
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability
    Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability
    		[PMID: 35643262]
    DU-145 IC50
    17.7 μM
    Compound: Olaparib
    Growth inhibition of human DU145 cells after 5 days by SRB assay
    Growth inhibition of human DU145 cells after 5 days by SRB assay
    		[PMID: 32484346]
    ES-2 IC50
    2.05 μM
    Compound: Olaparib
    Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days
    Antiproliferative activity against human ES2 cells assessed as reduction in cell viability measured after 7 days
    		[PMID: 35643262]
    HCC1937 IC50
    10.3 μM
    Compound: Olaparib, KU-59436, AZD 2281
    Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay
    Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay
    		[PMID: 24398383]
    HCC1937 IC50
    13 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as cell growth inhibition
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as cell growth inhibition
    		[PMID: 34091044]
    HCC1937 IC50
    22.03 μM
    Compound: A1
    Antiproliferative activity against human HCC1937 cells harboring BRCA2 mutant assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human HCC1937 cells harboring BRCA2 mutant assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    HCC1937 IC50
    38.2 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    HCC1937 IC50
    4.97 μM
    Compound: Olaparib
    Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay
    Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay
    		[PMID: 28763648]
    HCC1937 IC50
    6510 nM
    Compound: Ola
    Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition
    Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition
    		[PMID: 37616488]
    HCC1937 IC50
    8.1 μM
    Compound: OP
    Antiproliferative activity against HR-deficient human HCC1937 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against HR-deficient human HCC1937 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    HCC1937 IC50
    8.65 μM
    Compound: Olaparib
    Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay
    Antiproliferative activity against human HCC1937 cells after 3 days by MTT assay
    		[PMID: 28601509]
    HCC1937 IC50
    83.1 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA deficient human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against BRCA deficient human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34998039]
    HCC1937 IC50
    > 10 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA-1 deficient HCC1937 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    Antiproliferative activity against human BRCA-1 deficient HCC1937 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    		[PMID: 33740547]
    HCC1937 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    Antiproliferative activity against human HCC1937 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    		[PMID: 37616488]
    HCC1937 IC50
    > 200 μM
    Compound: Ola
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA1-deficient human HCC1937 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    HCC1937 IC50
    > 200 μM
    Compound: ola
    Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCC1937 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    HCC1937 IC50
    > 30 μM
    Compound: Olaparib
    Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability
    Antiproliferative activity against human HCC1937 cells assessed as reduction in cell viability
    		[PMID: 35643262]
    HCC827 IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    HCT-116 IC50
    1.37 μM
    Compound: Olaparib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    		[PMID: 37832229]
    HCT-116 IC50
    1.429 μM
    Compound: 1
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    HCT-116 IC50
    1.81 μM
    Compound: 1
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    HCT-116 IC50
    11.13 μM
    Compound: Olaparib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 37832229]
    HCT-116 IC50
    15.13 μM
    Compound: Olaparib
    Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay
    		[PMID: 28763648]
    HCT-116 IC50
    15.3 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against BRCA2-deficient human HCT-116 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    HCT-116 IC50
    2.28 μM
    Compound: 1
    Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under hypoxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    HCT-116 IC50
    2.65 μM
    Compound: 1
    Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    Cytotoxicity against human HCT-116 cells expressing N-terminally truncated POR/copGFP/puramycin resistance genes assessed as reduction in cell proliferation incubated for 4 hrs under oxic condition followed by incubation for 5 days under oxic condition by sulforhodamine B staining based analysis
    		[PMID: 37484567]
    HCT-116 IC50
    26.4 μM
    Compound: Olaparib
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36921527]
    HCT-116 IC50
    27.26 μM
    Compound: AZD2281
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    HCT-116 IC50
    5.56 μM
    Compound: Olaparib
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    		[PMID: 35504210]
    HCT-116 IC50
    5.86 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA2-deficient human HCT116 cells assessed as cell growth inhibition
    Antiproliferative activity against BRCA2-deficient human HCT116 cells assessed as cell growth inhibition
    		[PMID: 34091044]
    HCT-116 IC50
    7.32 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against BRCA2-mutated human HCT-116 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    HCT-116 IC50
    9 μM
    Compound: Olaparib
    Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells incubated for 72 hrs by MTT assay
    		[PMID: 37406384]
    HCT-116 IC50
    > 10 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA-2 deficient HCT-116 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    Antiproliferative activity against human BRCA-2 deficient HCT-116 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    		[PMID: 33740547]
    HCT-116 IC50
    > 200 μM
    Compound: A1
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    HCT-15 IC50
    32.08 μM
    Compound: OP
    Antiproliferative activity against HR-deficient human HCT-15 cells harboring BRCA2 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against HR-deficient human HCT-15 cells harboring BRCA2 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    HUVEC IC50
    4.6 μM
    Compound: Ola
    Inhibition of cell survival in VEGF165-treated HUVEC cells incubated for 48 hrs in presence of Pazopanib by CCK8 assay
    Inhibition of cell survival in VEGF165-treated HUVEC cells incubated for 48 hrs in presence of Pazopanib by CCK8 assay
    		[PMID: 37616488]
    HUVEC IC50
    > 100 μM
    Compound: Olaparib
    Inhibition of cell proliferation in HUVECs
    Inhibition of cell proliferation in HUVECs
    		[PMID: 38678823]
    HeLa EC50
    2.5 nM
    Compound: Olaparib, KU-59436, AZD 2281
    Inhibition of PARP-1 in human HeLa cells assessed as decrease of H2O2-induced PARylation after 3 hrs by fluorescence assay
    Inhibition of PARP-1 in human HeLa cells assessed as decrease of H2O2-induced PARylation after 3 hrs by fluorescence assay
    		[PMID: 24398383]
    HeLa IC50
    27.66 μM
    Compound: AZD2281
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    HeLa IC50
    30.48 μM
    Compound: A1
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    HeLa IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    HepG2 IC50
    42.4 μM
    Compound: Olaparib
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 30844273]
    Jurkat EC50
    0.06 μM
    Compound: AZD-2281
    Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide
    Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide
    		[PMID: 23850199]
    Jurkat EC50
    16 μM
    Compound: AZD-2281
    Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay
    Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay
    		[PMID: 23850199]
    K562 IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    L02 IC50
    25.8 μM
    Compound: Olaparib
    Cytotoxicity against human HL7702 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HL7702 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 30844273]
    L02 IC50
    60.67 μM
    Compound: AZD2281
    Antiproliferative activity against human L02 cells assessed as inhibition of cell growth at 20 uM incubated for 48 hrs by MTT assay
    Antiproliferative activity against human L02 cells assessed as inhibition of cell growth at 20 uM incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    LoVo EC50
    3.57 nM
    Compound: 2; AZD-2281
    Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay
    Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay
    		[PMID: 26652717]
    LoVo GI50
    237 nM
    Compound: 2; AZD-2281
    Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay
    Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay
    		[PMID: 26652717]
    MCF-10A IC50
    > 1000 μM
    Compound: Olaparib
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF-10A IC50
    > 1000 μM
    Compound: Olaparib
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF-10A IC50
    > 40 μM
    Compound: Ola
    Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay
    		[PMID: 38134746]
    MCF-10A IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    MCF-10A IC50
    > 80 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    MCF7 GI50
    13.2 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32088129]
    MCF7 IC50
    10580 nM
    Compound: Olaparib
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38039793]
    MCF7 IC50
    18.601 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 36462444]
    MCF7 IC50
    2.33 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    		[PMID: 37832229]
    MCF7 IC50
    232 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA proficient human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against BRCA proficient human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34998039]
    MCF7 IC50
    3.2 μM
    Compound: Olaparib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis
    Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis
    		[PMID: 38838546]
    MCF7 IC50
    35.24 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    MCF7 IC50
    36.24 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28763648]
    MCF7 IC50
    409.1 μM
    Compound: ola
    Cytotoxicity against human MCF7 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    MCF7 IC50
    93.87 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 37832229]
    MCF7 IC50
    < 1000 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF7 IC50
    > 100 μM
    Compound: Olaparib
    Inhibition of cell proliferation in human MCF7 cells
    Inhibition of cell proliferation in human MCF7 cells
    		[PMID: 38678823]
    MCF7 IC50
    > 1000 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MCF7 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 37616488]
    MCF7 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    		[PMID: 37616488]
    MCF7 IC50
    > 200 μM
    Compound: Ola
    Antiproliferative activity against BRCA-proficient human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA-proficient human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    MCF7 IC50
    > 40 μM
    Compound: Olaparib
    Antiproliferative activity against human MCF7 cells incubated for 2 to 5 days by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 2 to 5 days by MTT assay
    		[PMID: 31153806]
    MCF7 IC50
    > 50 μM
    Compound: 16
    Antiproliferative activity against human MCF7 cells
    Antiproliferative activity against human MCF7 cells
    		[PMID: 35531606]
    MDA-MB-231 GI50
    4.23 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32088129]
    MDA-MB-231 IC50
    0.69 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 7 days
    		[PMID: 35643262]
    MDA-MB-231 IC50
    0.8 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-231 IC50
    1.7 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-231 IC50
    24.84 μM
    Compound: AZD2281
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36183505]
    MDA-MB-231 IC50
    3.5 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-231 IC50
    30.7 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells harboring wild type BRCA and c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells harboring wild type BRCA and c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay
    		[PMID: 38477575]
    MDA-MB-231 IC50
    32.36 μM
    Compound: Olaparib
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 96 hrs by CCK8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 96 hrs by CCK8 assay
    		[PMID: 32726747]
    MDA-MB-231 IC50
    35.76 μM
    Compound: Ola
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    		[PMID: 38134746]
    MDA-MB-231 IC50
    39.51 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    MDA-MB-231 IC50
    4.47 μM
    Compound: OL
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35780655]
    MDA-MB-231 IC50
    4.47 μM
    Compound: Olaparib
    Antiproliferative activity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    Antiproliferative activity against wild type human MDA-MB-231 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    		[PMID: 35430559]
    MDA-MB-231 IC50
    5.35 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    		[PMID: 35504210]
    MDA-MB-231 IC50
    62.5 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    7.92 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 5 days by MTT assay
    		[PMID: 28601509]
    MDA-MB-231 IC50
    70.2 μM
    Compound: Olaparib
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by alamar blue reagent based analysis
    		[PMID: 38838546]
    MDA-MB-231 IC50
    73.31 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
    		[PMID: 36462444]
    MDA-MB-231 IC50
    8.48 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 7 days
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 7 days
    		[PMID: 34813314]
    MDA-MB-231 IC50
    8.48 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    MDA-MB-231 IC50
    < 1000 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    MDA-MB-231 IC50
    > 10 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA proficient MDA-MB-231 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    Antiproliferative activity against human BRCA proficient MDA-MB-231 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    		[PMID: 33740547]
    MDA-MB-231 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
    		[PMID: 37616488]
    MDA-MB-231 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    		[PMID: 37616488]
    MDA-MB-231 IC50
    > 200 μM
    Compound: Ola
    Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA-proficient human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    MDA-MB-231 IC50
    > 200 μM
    Compound: ola
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    MDA-MB-231 IC50
    > 30000 nM
    Compound: Olaparib
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38039793]
    MDA-MB-231 IC50
    > 40 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-231 cells incubated for 2 to 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 2 to 5 days by MTT assay
    		[PMID: 31153806]
    MDA-MB-231 IC50
    > 50 μM
    Compound: HY-10162
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37837671]
    MDA-MB-436 CC50
    0.0169 μM
    Compound: AZD2281
    Cytotoxicity against BRCA1-deficient human MDA-MB-436 cells by sulforhodamine B assay
    Cytotoxicity against BRCA1-deficient human MDA-MB-436 cells by sulforhodamine B assay
    		[PMID: 24815508]
    MDA-MB-436 CC50
    11.38 nM
    Compound: AZD2281
    Antiproliferative activity against BRCA1 deficient human MDA-MB-436 cells
    Antiproliferative activity against BRCA1 deficient human MDA-MB-436 cells
    		[PMID: 33246105]
    MDA-MB-436 CC50
    43.2 nM
    Compound: 3, AZD2281
    Cytotoxicity against human BRCA1-deficient MDA-MB-436 cells assessed as growth inhibition
    Cytotoxicity against human BRCA1-deficient MDA-MB-436 cells assessed as growth inhibition
    		[PMID: 23473053]
    MDA-MB-436 IC50
    0.018 μM
    Compound: 5; OLA
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 7 days by CCK-8 assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 7 days by CCK-8 assay
    		[PMID: 32924477]
    MDA-MB-436 IC50
    0.02 μM
    Compound: OL
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35780655]
    MDA-MB-436 IC50
    0.02 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA1 -/- MDA-MB-436 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    Antiproliferative activity against human BRCA1 -/- MDA-MB-436 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    		[PMID: 35430559]
    MDA-MB-436 IC50
    0.029 μM
    Compound: OP
    Antiproliferative activity against HR-deficient human MDA-MB-436 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against HR-deficient human MDA-MB-436 cells harboring BRCA1 mutant assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    MDA-MB-436 IC50
    0.1 μM
    Compound: 1; AZD2281
    Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 7 days by CCK-8 assay
    Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 7 days by CCK-8 assay
    		[PMID: 35785724]
    MDA-MB-436 IC50
    0.22 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-436 cells harboring BRCA1 mutation incubated for 2 to 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells harboring BRCA1 mutation incubated for 2 to 5 days by MTT assay
    		[PMID: 31153806]
    MDA-MB-436 IC50
    0.7 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-436 IC50
    1.5 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-436 IC50
    13.3 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against BRCA1-deficient human MDA-MB-436 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    MDA-MB-436 IC50
    23.89 μM
    Compound: Olaparib
    Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect
    Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect
    		[PMID: 38678823]
    MDA-MB-436 IC50
    39.3 nM
    Compound: 1; AZD-2281
    Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay
    Antiproliferative activity against human MDA-MB-436 cells after 7 days by CCK8 or SRB assay
    		[PMID: 28692916]
    MDA-MB-436 IC50
    4.6 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-436 IC50
    43.2 nM
    Compound: 1
    Antiproliferative activity against human MDA-MB-436 BRCA1-/- cells assessed as inhibition of cell growth incubated for 7 days by CCK-8 assay
    Antiproliferative activity against human MDA-MB-436 BRCA1-/- cells assessed as inhibition of cell growth incubated for 7 days by CCK-8 assay
    		[PMID: 37567056]
    MDA-MB-436 IC50
    8.9 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-436 cells
    Antiproliferative activity against human MDA-MB-436 cells
    		[PMID: 38838546]
    MDA-MB-436 IC50
    9000 nM
    Compound: Ola
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition
    		[PMID: 37616488]
    MDA-MB-436 IC50
    > 10000 nM
    Compound: Ola
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    Antiproliferative activity against human MDA-MB-436 cells assessed as cell growth inhibition in presence of 1:1 of compound:Pazopanib
    		[PMID: 37616488]
    MDA-MB-468 IC50
    0.6 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-468 IC50
    1.4 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-468 IC50
    1.83 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against BRCA-proficient human MDA-MB-468 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    MDA-MB-468 IC50
    10.1 μM
    Compound: Olaparib
    Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 33200929]
    MDA-MB-468 IC50
    13.72 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay
    		[PMID: 33309164]
    MDA-MB-468 IC50
    2.52 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 7 days by MTT assay
    		[PMID: 35504210]
    MDA-MB-468 IC50
    200 μM
    Compound: ola
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    MDA-MB-468 IC50
    3.4 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
    		[PMID: 37478560]
    MDA-MB-468 IC50
    35.57 μM
    Compound: 16
    Antiproliferative activity against human MDA-MB-468 cells
    Antiproliferative activity against human MDA-MB-468 cells
    		[PMID: 35531606]
    MDA-MB-468 IC50
    4.19 μM
    Compound: OL
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35780655]
    MDA-MB-468 IC50
    4.19 μM
    Compound: Olaparib
    Antiproliferative activity against human PTEN -/- MDA-MB-468 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    Antiproliferative activity against human PTEN -/- MDA-MB-468 cells assessed as reduction in cell viability incubated for 5 to 10 days by MTT assay
    		[PMID: 35430559]
    MDA-MB-468 IC50
    9.23 μM
    Compound: Olaparib
    Antiproliferative activity against human MDA-MB-468 cells harboring wild type BRCA1/2, HR-proficient and non-c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells harboring wild type BRCA1/2, HR-proficient and non-c-Met amplification assessed as inhibition of cell growth incubated for 7 days by MTT assay
    		[PMID: 38477575]
    MDA-MB-468 IC50
    > 10 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA proficient MDA-MB-468 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    Antiproliferative activity against human BRCA proficient MDA-MB-468 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    		[PMID: 33740547]
    MEF EC50
    14.6 μM
    Compound: AZD2281
    Cytotoxicity against mouse wild type MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    Cytotoxicity against mouse wild type MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    		[PMID: 29856625]
    MEF EC50
    49.6 μM
    Compound: AZD2281
    Cytotoxicity against mouse PARP1 deficient MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    Cytotoxicity against mouse PARP1 deficient MEF cells assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    		[PMID: 29856625]
    MEF EC50
    8.5 μM
    Compound: AZD2281
    Cytotoxicity against mouse PARP2 deficient MEF cells expressing PARP1 assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    Cytotoxicity against mouse PARP2 deficient MEF cells expressing PARP1 assessed as reduction in cell viability after 4 to 7 days by cell-titer glo assay
    		[PMID: 29856625]
    MIA PaCa-2 IC50
    8 μM
    Compound: Olaparib
    Cytotoxicity against human MIA PaCa-2 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human MIA PaCa-2 cells incubated for 72 hrs by MTT assay
    		[PMID: 37406384]
    MRC5 EC50
    5.83 μM
    Compound: 2; AZD-2281
    Cytotoxicity against human MRC5 cells
    Cytotoxicity against human MRC5 cells
    		[PMID: 26652717]
    MV4-11 IC50
    13.37 μM
    Compound: Olaparib
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 37832229]
    MV4-11 IC50
    2.36 μM
    Compound: Olaparib
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    		[PMID: 37832229]
    MX1 EC50
    23.2 nM
    Compound: 2; AZD-2281
    Cytotoxicity against BRCA1-deficient human MX1 cells
    Cytotoxicity against BRCA1-deficient human MX1 cells
    		[PMID: 26652717]
    MX1 IC50
    35.8 μM
    Compound: Ola
    Antiproliferative activity against BRCA1-deficient human MX1 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA1-deficient human MX1 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    MX1 IC50
    35.8 μM
    Compound: ola
    Cytotoxicity against human MX1 cells harbouring BRCA1 mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MX1 cells harbouring BRCA1 mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    MX1 IC50
    8.26 nM
    Compound: AZD2281
    Cytotoxicity against human MX1 cells harbouring BRCA1 and BRCA2 assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human MX1 cells harbouring BRCA1 and BRCA2 assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 37843892]
    NCI-H1299 IC50
    35.93 μM
    Compound: Cpd P
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
    		[PMID: 34038131]
    NCI-H1355 IC50
    33 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H1355 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H1355 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H1693 IC50
    19 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H1703 IC50
    20 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H1792 IC50
    16 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H1792 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H1792 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H1944 IC50
    25 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H1944 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H1944 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H2030 IC50
    34 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H2030 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H2030 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H2122 IC50
    38 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H2122 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H2122 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H23 IC50
    10 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human H23 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human H23 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H322M IC50
    50 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human NCI-H322M cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human NCI-H322M cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H441 IC50
    28 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human H441 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human H441 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCI-H460 IC50
    12 μM
    Compound: 1, AZD2281, KU0059436
    In vitro antiproliferative activity against human H460 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    In vitro antiproliferative activity against human H460 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 24521039]
    NCM460 IC50
    20.18 μM
    Compound: Olaparib
    Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of IDM by CCK8 assay
    		[PMID: 37832229]
    NCM460 IC50
    318.93 μM
    Compound: Olaparib
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36921527]
    NCM460 IC50
    67.15 μM
    Compound: Olaparib
    Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
    		[PMID: 37832229]
    NCM460 IC50
    > 200 μM
    Compound: A1
    Cytotoxicity against human NCM460 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Cytotoxicity against human NCM460 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    OCI-LY19 GI50
    0.849 μM
    Compound: Olaparib
    Cytotoxicity against human OCI-LY19 assessed as growth inhibition after 3 days by Alamar Blue assay
    Cytotoxicity against human OCI-LY19 assessed as growth inhibition after 3 days by Alamar Blue assay
    		[PMID: 26546219]
    PANC-1 IC50
    7 μM
    Compound: Olaparib
    Cytotoxicity against human PANC-1 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human PANC-1 cells incubated for 72 hrs by MTT assay
    		[PMID: 37406384]
    PC-3 IC50
    20.6 μM
    Compound: Olaparib
    Growth inhibition of human PC3 cells after 5 days by SRB assay
    Growth inhibition of human PC3 cells after 5 days by SRB assay
    		[PMID: 32484346]
    PEO1 IC50
    6.4 nM
    Compound: Chemical probe: Olaparib
    Inhibition of colony formation in human PEO1 cells incubated for 12 days by crystal violet staining based analysis
    Inhibition of colony formation in human PEO1 cells incubated for 12 days by crystal violet staining based analysis
    		[PMID: 31775874]
    Raji IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human Raji cells after 3 days by MTT assay
    Antiproliferative activity against human Raji cells after 3 days by MTT assay
    		[PMID: 28601509]
    SK-BR-3 IC50
    232 μM
    Compound: Ola
    Antiproliferative activity against BRCA-proficient human SKBR3 cells after 48 hrs by MTT assay
    Antiproliferative activity against BRCA-proficient human SKBR3 cells after 48 hrs by MTT assay
    		[PMID: 32222339]
    SK-BR-3 IC50
    232 μM
    Compound: ola
    Cytotoxicity against human SK-BR-3 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human SK-BR-3 cells harbouring wild type BRCA1/2 assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35393219]
    SK-BR-3 IC50
    < 1000 μM
    Compound: Olaparib
    Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
    		[PMID: 36603398]
    SK-OV-3 IC50
    166.9 μM
    Compound: A1
    Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    SK-OV-3 IC50
    1910 μM
    Compound: 3, AZD2281
    Cytotoxicity against human SKOV3 cells after 7 days by sulforhodamine B assay
    Cytotoxicity against human SKOV3 cells after 7 days by sulforhodamine B assay
    		[PMID: 23473053]
    SK-OV-3 IC50
    20.9 nM
    Compound: 3, AZD2281
    Inhibition of PARP1/PARP2 in human SKOV3 cells assessed as reduction in H2O2-induced PARylation incubated for 4 hrs prior to H2O2 treatment
    Inhibition of PARP1/PARP2 in human SKOV3 cells assessed as reduction in H2O2-induced PARylation incubated for 4 hrs prior to H2O2 treatment
    		[PMID: 23473053]
    SK-OV-3 IC50
    27.13 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against BRCA-proficient human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    SK-OV-3 IC50
    3.15 μM
    Compound: Olaparib
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 30844273]
    SUM149PT EC50
    0.4 μM
    Compound: Ola
    Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis
    Cytotoxicity against BRCA1-deficient human SUM149 cells measured after 6 days by microscopic analysis
    		[PMID: 31042381]
    SUM149PT EC50
    7 μM
    Compound: Ola
    Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis
    Cytotoxicity against BRCA1-proficient human SUM149 cells measured after 6 days by microscopic analysis
    		[PMID: 31042381]
    SW-620 IC50
    6 nM
    Compound: 28
    Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth
    Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth
    		[PMID: 36155354]
    SW-620 IC50
    6 nM
    Compound: 47, KU0059436, AZD-2281
    Ex vivo inhibition of PARP1 in human SW620 cells assessed as amount of poly(ADP-ribose) by whole cell assay
    Ex vivo inhibition of PARP1 in human SW620 cells assessed as amount of poly(ADP-ribose) by whole cell assay
    		[PMID: 18800822]
    SW-620 IC50
    > 10 μM
    Compound: Olaparib
    Antiproliferative activity against human BRCA-2 proficient SW-620 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    Antiproliferative activity against human BRCA-2 proficient SW-620 cells assessed as reduction in cell growth incubated for 7 days by cell titer-glo assay
    		[PMID: 33740547]
    SW1990 IC50
    19.4 μM
    Compound: Olaparib
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth after 3 days by MTT assay
    		[PMID: 35091172]
    SW1990 IC50
    3.63 μM
    Compound: Olaparib
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 7 days by MTT assay
    		[PMID: 35091172]
    SW1990 IC50
    4.93 μM
    Compound: Olaparib
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 5 days by MTT assay
    		[PMID: 35091172]
    SW1990 IC50
    5.73 μM
    Compound: Olaparib
    Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability after 4 days by MTT assay
    Antiproliferative activity against human SW1990 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 34813314]
    SW1990 IC50
    5.73 μM
    Compound: Olaparib
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth measured after 4 days by MTT assay
    		[PMID: 35091172]
    SW48 IC50
    4.6 μM
    Compound: Olaparib
    Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    Antiproliferative activity against BRCA2-deficient human SW48 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
    		[PMID: 38375763]
    SW480 IC50
    39.3 μM
    Compound: Olaparib
    Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 36921527]
    Sf9 IC50
    0.001 μM
    Compound: Olaparib
    Inhibition of full length human PARP1 expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    Inhibition of full length human PARP1 expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    		[PMID: 26546219]
    Sf9 IC50
    0.003 μM
    Compound: Olaparib
    Inhibition of human PARP2 (2 to 583 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    Inhibition of human PARP2 (2 to 583 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    		[PMID: 26546219]
    Sf9 IC50
    0.036 μM
    Compound: Olaparib
    Inhibition of recombinant human full length C-terminal His-tagged PARP1 expressed in Sf9 insect cells preincubated for 15 mins followed by NAD+ addition and measured after 40 mins by fluorescence based assay
    Inhibition of recombinant human full length C-terminal His-tagged PARP1 expressed in Sf9 insect cells preincubated for 15 mins followed by NAD+ addition and measured after 40 mins by fluorescence based assay
    		[PMID: 31153806]
    Sf9 IC50
    0.139 μM
    Compound: AZD-2281
    Inhibition of N-terminal GST-tagged human PARP1 expressed in a Baculovirus infected Sf9 insect cells using biotinylated substrate incubated for 1 hr by colorimetric method
    Inhibition of N-terminal GST-tagged human PARP1 expressed in a Baculovirus infected Sf9 insect cells using biotinylated substrate incubated for 1 hr by colorimetric method
    		[PMID: 31401008]
    Sf9 IC50
    0.5 nM
    Compound: Ola
    Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
    Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
    		[PMID: 31042381]
    Sf9 IC50
    1.2 nM
    Compound: Ola
    Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
    Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
    		[PMID: 31042381]
    Sf9 IC50
    1.7 μM
    Compound: Olaparib
    Inhibition of human TNKS2 (667 to 1166 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    Inhibition of human TNKS2 (667 to 1166 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    		[PMID: 26546219]
    Sf9 IC50
    1.8 x 10-3 μM
    Compound: Olaparib
    Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis
    Inhibition of recombinant human full length N-terminal GST- tagged PARP1 expressed in baculovirus infected sf9 cells using Colorimetric HRP as substrate incubated for 30 mins by UV/Vis spectrophotometer analysis
    		[PMID: 31442685]
    Sf9 IC50
    1.8 μM
    Compound: Olaparib
    Inhibition of full length human PARP6 expressed in a Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    Inhibition of full length human PARP6 expressed in a Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    		[PMID: 26546219]
    Sf9 IC50
    1.9 μM
    Compound: Olaparib
    Inhibition of human TNKS1 (1001 to 1327 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    Inhibition of human TNKS1 (1001 to 1327 residues) expressed in Baculovirus infected Sf9 insect cells using activated DNA as substrate after 1 hr by streptavidin-horseradish peroxidase-based luminescence assay
    		[PMID: 26546219]
    SiHa IC50
    > 200 μM
    Compound: A1
    Antiproliferative activity against human SiHa cells assessed as inhibition of cell proliferation incubated for 72 hrs
    Antiproliferative activity against human SiHa cells assessed as inhibition of cell proliferation incubated for 72 hrs
    		[PMID: 38776379]
    T47D IC50
    > 50 μM
    Compound: Olaparib
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    T98G IC50
    1.6 nM
    Compound: 1
    Inhibition of PARP1 in human T98G cells incubated for 60 mins by immunofluorescence assay
    Inhibition of PARP1 in human T98G cells incubated for 60 mins by immunofluorescence assay
    		[PMID: 26469301]
    THP-1 IC50
    32.3 μM
    Compound: Olaparib
    Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay
    Antiproliferative activity against human THP-1 cells expressing BRD4 assessed as inhibition of cell growth measured after 3 days by MTT assay
    		[PMID: 35091172]
    U-937 IC50
    21.81 μM
    Compound: Olaparib
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
    		[PMID: 28601509]
    V79 CC50
    8.985 μM
    Compound: AZD2281
    Cytotoxicity against Chinese hamster V79 cells by sulforhodamine B assay
    Cytotoxicity against Chinese hamster V79 cells by sulforhodamine B assay
    		[PMID: 24815508]
    V79 CC50
    > 10 μM
    Compound: 3, AZD2281
    Cytotoxicity against Chinese hamster V79 cells expressing wild type BRCA2 assessed as growth inhibition
    Cytotoxicity against Chinese hamster V79 cells expressing wild type BRCA2 assessed as growth inhibition
    		[PMID: 23473053]
    V79 IC50
    4.76 μM
    Compound: OP
    Antiproliferative activity against Chinese hamster V79 cells harboring wild type BRCA2 assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    Antiproliferative activity against Chinese hamster V79 cells harboring wild type BRCA2 assessed as cell proliferation inhibition incubated for 7 days by SRB assay
    		[PMID: 37605459]
    V79 IC50
    >= 10000 nM
    Compound: 1; AZD-2281
    Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay
    Cytotoxicity against BRCA2 expressing Chinese hamster V79 cells after 3 days by CCK8 or SRB assay
    		[PMID: 28692916]
    In Vitro

    Olaparib (AZD2281) is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Olaparib is applied to SW620 cell lysates, and identified the IC50 for PARP-1 inhibition to be around 6 nM and the total ablation of PARP-1 activity to be at concentrations of 30 100 nM[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Olaparib Related Antibodies
    In Vivo

    Animals bearing SW620 xenografted tumors are treated with Olaparib (10 mg/kg, p.o.) in combination with NSC 362856 (TMZ) (50 mg/kg, p.o.) once daily for 5 consecutive days, after which the tumors are left to grow out[1]. Olaparib increases vascular perfusion in Calu-6 tumors established in a DWC model. Administration of olaparib(50 mg/kg, p.o.) as a single agent (top panel) or in combination with radiation (bottom panel) results in an increase in fluorescence intensity in the Calu-6 tumors[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    434.46

    Formula

    C24H23FN4O3
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(C1=CC(CC(C2=C3C=CC=C2)=NNC3=O)=CC=C1F)N4CCN(C(C5CC5)=O)CC4
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (230.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3017 mL 11.5085 mL 23.0171 mL
    5 mM 0.4603 mL 2.3017 mL 4.6034 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (11.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (11.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.98%

    SDS (584 KB)

    COA (250 KB) HNMR (221 KB) LCMS (120 KB) Elemental Analysis Report (108 KB)

    Handling Instructions (2659 KB)
    References
    Kinase Assay
    [1]

    This assay determined the ability of Olaparib to inhibit PARP-1 enzyme activity. PARP-2 activity inhibition is measured by using a variation of the PARP-1 assay in which PARP-2 protein (recombinant) is bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity is measured following 3H-NAD+ DNA additions. After washing, scintillant is added to measure 3H-incorporated ribosylations. For tankyrase-1, an AlphaScreen assay is developed in which HIS-tagged recombinant TANK-1 protein is incubated with biotinylated NAD+ in a 384-well ProxiPlate assay. Alpha beads are added to bind the HIS and biotin tags to create a proximity signal, whereas the inhibition of TANK-1 activity is directly proportional to the loss of this signal. All experiments are repeated at least three times[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [1]

    The PF50 value is the potentiation factor, which is calculated as the ratio of the IC50 of the control growth with alkylating agent methylmethane sulfonate (MMS) divided by the IC50 of the MMS combined with the PARP inhibitor. HeLa B cells are used, and Olaparib is tested at a fixed 200 nM concentration for screening with MMS. For the testing of Olaparib on the SW620 colorectal cell line, the concentrations that are used are 1, 3, 10, 100 and 300 nM. Cell growth is assessed by the use of the sulforhodamine B (SRB) assay[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    Mice bearing 220-250 mm3 tumors are randomized into 4 treatment groups (n=5): A; vehicle control (10% DMSO in PBS/10% 2-hydroxy-propyl-β-cyclodextrin daily for 5 days by oral gavage), B; Olaparib (50 mg/kg daily for 5 days by oral gavage), C; 10 Gy fractionated radiotherapy (2 Gy daily for 5 days), D; Olaparib and 10 Gy (5×2 Gy) fractionated radiotherapy (with olaparib given 30 min prior to each daily 2 Gy dose of radiation). Tumor volume measurements are determined daily until they reached 1000 mm3. The number of days for each individual tumor to quadruple in size from the start of the treatment (relative tumor volume×4; RTV4) is calculated for the individual tumors in each group.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3017 mL 11.5085 mL 23.0171 mL 57.5427 mL
    5 mM 0.4603 mL 2.3017 mL 4.6034 mL 11.5085 mL
    10 mM 0.2302 mL 1.1509 mL 2.3017 mL 5.7543 mL
    15 mM 0.1534 mL 0.7672 mL 1.5345 mL 3.8362 mL
    20 mM 0.1151 mL 0.5754 mL 1.1509 mL 2.8771 mL
    25 mM 0.0921 mL 0.4603 mL 0.9207 mL 2.3017 mL
    30 mM 0.0767 mL 0.3836 mL 0.7672 mL 1.9181 mL
    40 mM 0.0575 mL 0.2877 mL 0.5754 mL 1.4386 mL
    50 mM 0.0460 mL 0.2302 mL 0.4603 mL 1.1509 mL
    60 mM 0.0384 mL 0.1918 mL 0.3836 mL 0.9590 mL
    80 mM 0.0288 mL 0.1439 mL 0.2877 mL 0.7193 mL
    100 mM 0.0230 mL 0.1151 mL 0.2302 mL 0.5754 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Olaparib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Olaparib763113-22-0AZD2281 KU0059436AZD 2281AZD-2281KU0059436KU 0059436KU-0059436PARPAutophagyMitophagypoly ADP ribose polymerase Mitochondrial AutophagyorallyPARP1PARP2Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Olaparib
    Cat. No.:
    HY-10162
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (584 KB) Français - FR (584 KB) Deutsch - DE (584 KB) Norwegian - NO (584 KB) Español - ES (584 KB) Swedish - SV (584 KB) Italian - IT (584 KB) Korean - KR (584 KB) Portuguese - PT (584 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.